Glucosamine is a compound produced naturally in the body and found in cartilage, where it is a building block of the molecules that give joints their shock-absorbing properties. As an oral supplement — usually sold as glucosamine sulphate or glucosamine hydrochloride, at prices of around €17–22 per pack — it has been marketed for joint health for decades. The ACR 2019 guideline strongly recommends against glucosamine for knee, hip and hand osteoarthritis 1. OARSI 2019 places it on its non-recommended list 2. NICE NG226 states: "Do not offer glucosamine… to people to manage osteoarthritis" 3. No joint-health claim is authorised by the European Food Safety Authority for glucosamine products under Regulation (EC) No 1924/2006 78.
What is glucosamine?
Glucosamine is an amino sugar — a small molecule the body synthesises from glucose and uses as a raw material for glycosaminoglycans, the long-chain polysaccharides that form the matrix of cartilage and synovial fluid. The theory behind supplementation is straightforward: if cartilage is wearing down in osteoarthritis, supplying the building blocks might slow that process or reduce inflammation. It is a plausible mechanism. The problem is that plausibility is not the same as clinical effect, and the decades of clinical trials have not delivered what the theory promised 45.
Over-the-counter glucosamine supplements come in two main forms: glucosamine sulphate and glucosamine hydrochloride. They are not the same as the prescription-grade crystalline glucosamine sulphate used in some European clinical studies, which has different bioavailability and manufacturing standards. This distinction matters, and we return to it below.
What did the big trials actually find?
The landmark clinical test was the Glucosamine/Chondroitin Arthritis Intervention Trial — known as GAIT — published in the New England Journal of Medicine in 2006 4. It was a multicentre, double-blind, placebo- and celecoxib-controlled trial involving 1,583 patients with symptomatic knee osteoarthritis. The primary outcome was a 20% reduction in pain. Glucosamine alone, chondroitin sulphate alone, and the combination did not differ significantly from placebo on the primary endpoint in the overall population. In a pre-specified subgroup with moderate-to-severe pain, the combination showed a statistically significant response — but this subgroup finding, in a secondary analysis, is not strong enough to reverse the primary result, and subsequent trials have not consistently replicated it 4.
A 2018 systematic review and meta-analysis of randomised placebo-controlled trials — pooling data across the strongest available studies — found that oral glucosamine produced a small statistically significant reduction in visual analogue scale (VAS) pain scores but no significant effect on the WOMAC index (a composite score of pain, stiffness and function that is the standard functional outcome measure in osteoarthritis research) 5. The combination of glucosamine and chondroitin did not even show the VAS reduction: the pooled effect was essentially zero (weighted mean difference −0.28 mm, 95% CI −8.87 to 8.32) 5. The effect sizes where any signal appeared were small and fell below the threshold for clinical relevance.
"Glucosamine is strongly recommended against for patients with knee osteoarthritis." — Kolasinski SL et al., ACR/Arthritis Foundation Guideline 2019 [1]
What do the major international guidelines conclude?
Three major independent clinical guideline bodies have looked at this evidence and reached the same conclusion. The American College of Rheumatology (ACR) and Arthritis Foundation 2019 guideline — covering the management of osteoarthritis of the hand, hip and knee — gives glucosamine a strong recommendation against, upgraded from a previous conditional recommendation against 1. The upgrade to "strong" means the panel was highly confident the harms (or in this case, the cost and false hope) outweigh the benefits for the vast majority of patients.
The Osteoarthritis Research Society International (OARSI) 2019 guideline for non-surgical management of knee, hip and polyarticular osteoarthritis lists glucosamine among its explicitly non-recommended treatments 2. NICE guideline NG226, published in 2022 and covering osteoarthritis in adults in England and Wales, states in §1.4.6: "Do not offer glucosamine or strong opioids to people to manage osteoarthritis" — placing it in the same sentence as the most powerful painkillers that are no longer considered appropriate for this condition, on grounds of insufficient evidence of benefit 3.
Why does every pharmacy still sell it?
This is the question that matters, and the answer has two parts. First, glucosamine is commercially very successful — it is among the highest-volume joint supplements in Italy and across Europe, retailing at around €17–22 per pack, with high repeat-purchase rates from patients who believe it is helping them. Pharmacies are retail businesses; they stock what sells. Second, and more importantly: because glucosamine is sold as a food supplement rather than a medicine, it is not regulated by the same evidence requirements. A food supplement does not need to prove efficacy before going on sale. It only needs to be safe.
Under EU Regulation (EC) No 1924/2006 on nutrition and health claims, any claim that a food or supplement has a beneficial effect on health must be authorised by EFSA on the basis of scientific evidence 7. Glucosamine carries no authorised joint-health claim in the EU register 8. What you see on the packaging — language about "contributing to the maintenance of healthy cartilage", for example — is typically general, carefully worded marketing copy that falls short of a health claim, not a claim that has passed EFSA scrutiny. The regulation forbids the kind of explicit claim the product implicitly promises. That gap is what you are paying for.
If you are already taking it
If you are currently taking glucosamine and feel it is helping you, talk to your doctor or pharmacist before you stop — not because stopping is dangerous, but because they can help you think through whether what you are experiencing is a real effect, a placebo response, or natural variation in your symptoms over time. Do not stop abruptly because of an article you read. What I can tell you is that saving €17–22 every few weeks is not a trivial amount over a year, and the guidelines currently do not support spending that money on this supplement for joint pain.
Glucosamine is well tolerated by most people, and if your doctor has reviewed your full medication list and has no concerns, there is no urgent medical reason to stop. The cost-benefit calculation is simply unfavourable according to the best available evidence 123.
What the label cannot tell you
EU law prohibits manufacturers from making specific health claims on supplements that have not been authorised by EFSA 7. For glucosamine, no claim relating to joint health or cartilage maintenance has been approved 8. This means the gap between what the product implies and what it is legally allowed to state is deliberately large. A product sold as support for "joint comfort" or "cartilage health" cannot legally claim to reduce pain in osteoarthritis — because that claim would require pharmaceutical-level evidence and a marketing authorisation as a medicine.
When you see marketing language implying that a supplement "supports" or "nourishes" your joints without any cited clinical evidence, you are reading copy engineered to stay below the legal threshold for a regulated claim. That is not dishonesty in the legal sense — it is the system working as designed. But it means you should not read supplement packaging as clinical guidance.
What actually helps in osteoarthritis
The treatments with genuinely strong evidence for knee osteoarthritis are exercise — particularly strength training and low-impact aerobic activity — and, for people who are overweight, weight loss 23. Topical non-steroidal anti-inflammatory drugs (NSAIDs) have good evidence for knee OA and are recommended as a first pharmacological step by NICE NG226 3. Intra-articular corticosteroid injections can provide short-term relief when other options are insufficient 3.
Among dietary supplements, the picture is genuinely more complicated for other compounds — hydrolysed collagen, for example, has emerging evidence in specific populations — but glucosamine and chondroitin, on the current evidence and according to the current guidelines, do not make the list. Exercise and load management do. An osteopathic assessment can help identify the specific movement patterns, joint loading and postural factors contributing to your joint pain — which is where I can actually help.
FAQ
Does glucosamine work for joint pain?
The evidence is weak and inconsistent. The large GAIT trial (1,583 patients, NEJM 2006) found glucosamine did not significantly reduce pain compared with placebo in the overall knee osteoarthritis population 4. A 2018 systematic review and meta-analysis found some reduction in VAS pain scores but no significant effect on the total WOMAC index — the standard functional outcome measure 5. This is why the ACR 2019, OARSI 2019 and NICE NG226 guidelines all recommend against it 123.
Is glucosamine dangerous?
At typical over-the-counter doses, glucosamine appears to be well tolerated and does not carry serious known risks for most people. The issue is not safety — it is that the evidence of benefit is insufficient to justify recommending it. People on warfarin or other anticoagulants should check with their doctor, as interactions have been reported.
What exactly do the guidelines say about glucosamine?
Three major international guidelines give the clearest possible verdict. The ACR 2019 guideline strongly recommends against glucosamine for knee, hip and hand osteoarthritis 1. OARSI 2019 lists glucosamine among its non-recommended treatments 2. NICE NG226 (UK, 2022) states: "Do not offer glucosamine… to people to manage osteoarthritis" 3. This is unusually consistent across independent bodies.
What about the prescription form — crystalline glucosamine sulfate?
This is the one honest complication in the picture. The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) 2019 algorithm includes prescription-grade crystalline glucosamine sulfate — a patented pharmaceutical form — as a step-1 background therapy, citing evidence of modest symptom benefit and a possible structural effect 6. This is a minority view among guidelines, and the distinction from the over-the-counter supplement form matters: the pharmaceutical grade has different bioavailability and study data. If you are prescribed a medicine-class glucosamine sulfate by a rheumatologist, that is a different conversation from buying a supplement in a pharmacy.
If glucosamine does not work, what should I take instead?
For joint pain, the strongest non-pharmacological evidence supports exercise — specifically strength training and aerobic activity. For dietary approaches, vitamin C contributes to normal collagen formation for cartilage (the only EU-authorised claim in this area). Some evidence supports hydrolysed collagen at 10g/day for three months or more. Your doctor can discuss appropriate pharmacological options — topical NSAIDs have good evidence for knee OA. An osteopathic assessment can also help identify the movement and load factors driving your symptoms.
Get the printable sheet (free)
References
- Kolasinski SL et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220–233.
- Bannuru RR et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589.
- NICE guideline NG226 — Osteoarthritis in over 16s: diagnosis and management. §1.4.6: Do not offer glucosamine to people to manage osteoarthritis. Published October 2022.
- Clegg DO et al. — Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis (GAIT trial). N Engl J Med. 2006;354(8):795–808. PMID 16495392.
- Simental-Mendía M et al. — Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis. Rheumatol Int. 2018;38(8):1413–1428. PMID 29947998.
- Bruyère O et al. — An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–350.
- European Parliament and Council — Regulation (EC) No 1924/2006 on nutrition and health claims made on foods. EUR-Lex.
- EFSA — EU Register of authorised health claims: glucosamine search (no joint-health claim authorised). European Commission.
- Towheed TE et al. — Glucosamine therapy for treating osteoarthritis (Cochrane review, last assessed as up-to-date 2005). Cochrane Database Syst Rev. 2005;(2):CD002946.
- American College of Rheumatology — Osteoarthritis Guideline: patient summary and recommendations overview (ACR website).
- OARSI — Non-surgical management of knee, hip and polyarticular OA: guideline overview (OARSI journal 2019).